This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sadowy, E.
Right arrow Articles by Hryniewicz, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sadowy, E.
Right arrow Articles by Hryniewicz, W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2005, p. 2126-2129, Vol. 49, No. 5
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.5.2126-2129.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

High Genetic Diversity of Ciprofloxacin-Nonsusceptible Isolates of Streptococcus pneumoniae in Poland

Ewa Sadowy,* Radoslaw Izdebski, Anna Skoczynska, Marek Gniadkowski, and Waleria Hryniewicz

National Institute of Public Health, Chelmska 30/34, 00-725 Warsaw, Poland

Received 18 November 2004/ Returned for modification 24 December 2004/ Accepted 27 January 2005


arrow
ABSTRACT
 
We have analyzed the susceptibility to ciprofloxacin of 697 pneumococcal isolates collected in 1998-2002 in Poland from patients with respiratory tract diseases. Thirty-one ciprofloxacin-nonsusceptible isolates (MICs, ≥4 µg/ml) were identified, of which two were resistant to levofloxacin (MIC, 8 µg/ml). Serotyping, pulsed-field gel electrophoresis, multilocus sequence typing, and the analysis of resistance determinants showed their great genetic diversity.


arrow
TEXT
 
The constant increase in resistance of Streptococcus pneumoniae to ß-lactams, macrolides, and tetracyclines has evoked a need for alternative options in the treatment of pneumococcal infections. New fluoroquinolones, such as levofloxacin and moxifloxacin, are now considered to play this role in the case of infections in adults. However, the first pneumococci resistant to these compounds have appeared in some countries (5, 8, 9, 17, 19, 21, 32), and therapeutic failures have been reported (22). Mechanisms of quinolone resistance in S. pneumoniae include increased activity of the membrane pump PmrA (13) and modifications of the cellular drug targets topoisomerase IV (ParC/ParE) and DNA gyrase (GyrA/GyrB) (11, 18, 28, 29), located in their so-called quinolone-resistance-determining regions (QRDRs) (28, 29). Selection of these mechanisms is partially exerted by the common use of an older quinolone, ciprofloxacin, which is not recommended as an antipneumococcal agent. Each of the mechanisms alone confers low-level ciprofloxacin nonsusceptibility and increases the risk of acquisition of further changes (14). The accumulation of mutations in both ParC/ParE and GyrA/GyrB (3, 7, 18, 30, 32) results in high-level nonsusceptibility to ciprofloxacin and resistance to the newer compounds. Therefore, ciprofloxacin nonsusceptibility is an important measure of the actual and potential quinolone resistance of pneumococci (33).

The situation concerning resistance to quinolones in S. pneumoniae in Central and Eastern Europe has not been investigated yet. The aim of our study was to evaluate the frequency of ciprofloxacin nonsusceptibility in S. pneumoniae in Poland and to reveal the genetic relatedness among nonsusceptible isolates.

(This work was presented at RGPI-2, 10 to 12 December, 2004, Berlin, Germany.)

Six-hundred ninety-seven S. pneumoniae isolates were obtained from individual patients with lower respiratory tract diseases between 1998 and 2002 in 40 medical centers in 26 cities. The isolates were derived from sputum (562 isolates, 80.6%), bronchoalveolar lavage (75 isolates, 10.8%), and transtracheal aspirate (60 isolates, 8.6%). MICs of ciprofloxacin (Bayer AG, Leverkusen, Germany) were evaluated by the National Committee for Clinical Laboratory Standards microdilution method (26); due to the lack of an accepted breakpoint, a pneumococcal isolate was considered nonsusceptible to ciprofloxacin when its MIC was ≥4 µg/ml (1, 8, 17). Such isolates were tested as described above with levofloxacin (Aventis Pharma, Romainville, France), moxifloxacin (Bayer AG, Leverkusen, Germany), penicillin (Sigma Chemical Company, St. Louis, Mo.), and erythromycin (Fluka, Buchs, Switzerland), using the National Committee for Clinical Laboratory Standards-approved breakpoints (26). PCR amplification and sequencing of QRDRs of gyrA, gyrB, parC, and parE genes was performed as described by Pan et al. (29). The reserpine-mediated inhibition of quinolone efflux was performed according to the method of Broskey et al. (4). Serotypes of the isolates were determined by the capsular swelling method at the Statens Serum Institute (Copenhagen, Denmark). Pulsed-field gel electrophoresis (PFGE) typing was performed as described by Lefèvre et al. (23); isolates were considered indistinguishable when they shared PFGE patterns and were considered related when they showed a difference of one to three bands. Multilocus sequence typing (MLST) was performed as proposed by Enright and Spratt (10); the Internet-accessible database (http://www.mlst.net) was used to assign numbers to alleles and sequence types (STs).

Thirty-one isolates, i.e., 4.4% of the all 697 isolates studied (Table 1), appeared nonsusceptible to ciprofloxacin, and they originated from 12 towns uniformly distributed in the country. Among these isolates, five were penicillin nonsusceptible, two were erythromycin resistant and two (BY-2 and BY-3; 0.3%) were resistant to levofloxacin (MIC, 8 µg/ml) and intermediate to moxifloxacin (MIC, 2 µg/ml), which correlated with their high-level ciprofloxacin nonsusceptibility (MICs, ≥32 µg/ml). Both quinolone-resistant isolates were penicillin and erythromycin susceptible. No significant difference in patients' ages between the ciprofloxacin-nonsusceptible and -susceptible groups was found (56.7 ± 19.6 and 52.8 ± 21.2 years, respectively; P = 0.3). The prevalence of ciprofloxacin nonsusceptibility in S. pneumoniae is generally low worldwide; e.g., in the United States, it remained within the range of 1.2 to 1.6% during 1994-2000 (6). However, in some countries, such as Hong Kong, Ireland, and Spain, it has reached levels of 17.8%, 15.2%, and 5%, respectively (12, 15, 17). In Canada, the frequency of ciprofloxacin nonsusceptibility increased from 0% in 1993 to 1.7% in 1997-1998 following the increase in quinolone consumption (8). Therefore, while the observed rate of resistance to newer quinolones remains low in Poland (0.3%), the ciprofloxacin nonsusceptibility seems to be significant. Ciprofloxacin was introduced into the country in 1991; in 2002, its consumption in ambulatory care in Poland amounted to 0.5 defined daily doses/1,000 inhabitants/day, while in Spain it was 2.3-fold higher (16).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Ciprofloxacin-nonsusceptible S. pneumoniae isolates: serotypes, susceptibility to quinolones, resistance determinants, PFGE types, and MLST characteristics

The reserpine-inhibited efflux was active in 19 ciprofloxacin-nonsusceptible isolates and absent in 10 isolates (Table 1). In 11 isolates, the efflux was the sole determinant of nonsusceptibility. Alterations in QRDRs of ParC/ParE or GyrA/GyrB were identified for 18 isolates, and they included predominantly single ParC mutations (15 isolates) at mutational hot spot Ser79 or Asp83 (29). Among them, the Ser79Phe substitution was the most common (10 isolates). A single isolate possessed the Pro454Ser substitution in ParE, which has been described before for clinical isolates (7, 9) and laboratory mutants (25). The role of some of the other observed substitutions is most probably negligible (3, 20, 31). The two levofloxacin-resistant isolates, in addition to the ParC mutation Asp83Asn, had the hot spot alteration Ser81Phe in GyrA (2). The proportions of frequency of the mechanisms of ciprofloxacin nonsusceptibility vary among countries; however, the alterations only in ParC/ParE seem to dominate (3, 4, 6, 11, 29, 30), reflecting the fact that ParC/ParE is a primary target for ciprofloxacin in pneumococcus (28, 29).

Eighteen serotypes were observed among the ciprofloxacin-nonsusceptible pneumococci, with the most common, 23F, being represented by five isolates (Table 1). Twenty-eight PFGE patterns were identified, and these could be classified into 25 distinct types. Three of the types (G, H, and Q) were differentiated further into two subtypes each, and one of these contained the levofloxacin-resistant isolates (type G). The results indicated the remarkable clonal diversity of ciprofloxacin-nonsusceptible S. pneumoniae in Poland, and suggested that they probably arose from multiple independent selection events. Such variability seems to be typical for the organism (24, 27), except in some countries, e.g., Spain, where clones Spain9V-3 and Spain23F-1 constitute 30% of ciprofloxacin-nonsusceptible pneumococci (1). Sixteen isolates, representing serotypes associated with the multiresistant international clones (6A, 6B, 9V, 14, 15A, 19A, 19F, and 23F), and the two levofloxacin-resistant isolates were subjected to MLST (Table 1). In general, the isolates were unrelated to the international clones; however, two and one isolates represented Spain9V-3 (ST156) and Spain23F-1 (ST81) clones, respectively. This observation is noteworthy, since the effective spread of such clones may quickly increase the rate of quinolone nonsusceptibility in a local pneumococcal population, as shown in Hong Kong (17). The levofloxacin-resistant isolates belonged to ST191, which was observed before in some European and South American countries (http://www.mlst.net).

In summary, the current frequency of ciprofloxacin-nonsusceptible pneumococci in Poland, although not alarming, is remarkable. The circulation of strains that are prone to develop resistance also to newer quinolones may compromise this therapeutic option in the future and undoubtedly requires permanent epidemiological surveillance.


arrow
ACKNOWLEDGMENTS
 
We thank Pawel Grzesiowski for help with statistical calculations and Anna Klarowicz and Agnieszka Mrówka for their technical assistance.

This study was partially financed by a grant from the Polish Committee for Scientific Research (3P0A 062 23). We acknowledge the use of the pneumococcal MLST database which is located at Imperial College, London, and is funded by the Wellcome Trust.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Molecular Microbiology, National Institute of Public Health, ul. Chelmska 30/34, 00-725 Warsaw, Poland. Phone: 48 22 851 43 88. Fax: 48 22 841 29 49. E-mail: ewasadowy{at}cls.edu.pl. Back


arrow
REFERENCES
 
    1
  1. Alou, L., M. Ramirez, C. García-Rey, J. Prieto, and H. de Lancastre. 2001. Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones. Antimicrob. Agents Chemother. 45:2955-2957.[Abstract/Free Full Text]
    2. 2
  2. Barnard, F. M., and A. Maxwell. 2001. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser83 and Asp87. Antimicrob. Agents Chemother. 45:1994-2000.[Abstract/Free Full Text]
    3. 3
  3. Bast, D. J., D. E. Low, C. L. Duncan, L. Kilburn, L. A. Mandell, R. J. Davidson, and J. S. C. de Azavedo. 2000. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44:3049-3054.[Abstract/Free Full Text]
    4. 4
  4. Broskey, J., K. Coleman, M. N. Gwynn, L. McCloskey, C. Traini, L. Voelker, and R. Warren. 2000. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 45(Suppl. S1):95-99.[Abstract]
    5. 5
  5. Brown, S. D., D. J. Farrel, and I. Morrisey. 2004. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US study. J. Clin. Microbiol. 42:4980-4987.[Abstract/Free Full Text]
    6. 6
  6. Brueggemann, A. B., S. L. Coffman, P. Rhomberg, H. Huynh, L. Almer, A. Nilius, R. Flamm, and G. V. Doern. 2002. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. 46:680-688.[Abstract/Free Full Text]
    7. 7
  7. Canton, R., M. Morosini, M. C. Enright, and I. Morrissey. 2003. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J. Antimicrob. Chemother. 52:944-952.[Abstract/Free Full Text]
    8. 8
  8. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-238.[Abstract/Free Full Text]
    9. 9
  9. Davies, T. A., R. Goldschmidt, S. Pfleger, M. Loeloff, K. Bush, D. F. Sahm, and A. Evangelista. 2003. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J. Antimicrob. Chemother. 52:168-175.[Abstract/Free Full Text]
    10. 10
  10. Enright, M. C., and B. G. Spratt. 1998. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144:3049-3060.[Abstract/Free Full Text]
    11. 11
  11. Fukuda, H., and K. Hiramatsu. 1999. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:410-412.[Abstract/Free Full Text]
    12. 12
  12. Garcia-Rey, C. L., L. Aguillar, and F. Baquero. 2000. Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain. Antimicrob. Agents Chemother. 44:3481-3482.[Free Full Text]
    13. 13
  13. Gill, M. J., N. P. Brenwald, and R. Wise. 1999. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:187-189.[Abstract/Free Full Text]
    14. 14
  14. Gillespie, S. H., L. L. Voelker, J. E. Ambler, C. Traini, and A. Dickens. 2003. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb. Drug Res. 9:17-24.
    15. 15
  15. Goldsmith, C. E., J. E. Moore, P. G. Murphy, and J. E. Ambler. 1998. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland. J. Antimicrob. Chemother. 41:420-421.[Free Full Text]
    16. 16
  16. Goosens, H., M. Ferech, R. V. Stichele, M. Elseviers, and the ESAC Project Group. 2005. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365:579-587.[Medline]
    17. 17
  17. Ho, P. L., R. W. H. Yung, D. N. C. Tsang, T. L. Que, M. Ho, W. H. Seto, T. K. Ng, W. C. Yam, and W. W. S. Ng. 2001. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. 48:659-665.[Abstract/Free Full Text]
    18. 18
  18. Janoir, C., V. Zeller, M.-D. Kitzis, N. J. Moreau, and L. Gutmann. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.[Abstract]
    19. 19
  19. Johnson, C. N., W. H. Benjamin, Jr., S. A. Moser, S. K. Hollingshead, X. Zheng, M. J. Crain, M. H. Nahm, and K. B. Waites. 2003. Genetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America. J. Clin. Microbiol. 41:2458-2464.[Abstract/Free Full Text]
    20. 20
  20. Jones, M. E., D. F. Sahm, N. Martin, S. Scheuring, P. Heisig, C. Thornsberry, K. Köhrer, and F.-J. Schmitz. 2000. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob. Agents Chemother. 44:462-466.[Abstract/Free Full Text]
    21. 21
  21. Jones, M. E., J. A. Karlowsky, R. Blosser-Middleton, I. A. Critchley, E. Karginova, C. Thornsberry, and D. F. Sahm. 2002. Longitudinal assessment of antipneumococcal susceptibility in the United States. Antimicrob. Agents Chemother. 46:2651-2655.[Abstract/Free Full Text]
    22. 22
  22. Klugman, K. P. 2002. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur. Respir. J. 20(Suppl. 36):S3-S8.[Abstract/Free Full Text]
    23. 23
  23. Lefèvre, J. C., G. Faucon, A. M. Sicard, and A. M. Gasc. 1993. DNA fingerprinting of Streptococcus pneumoniae strains by pulsed-field gel electrophoresis. J. Clin. Microbiol. 31:2724-2728.[Abstract/Free Full Text]
    24. 24
  24. Montanari, M. P., E. Tili, I. Cochetti, M. Mingoia, A. Manzin, and P. E. Varaldo. 2004. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy. Microb. Drug Resist. 10:209-217.[Medline]
    25. 25
  25. Nagai, K., T. A. Davies, G. A. Pankuch, B. E. Dewasse, M. R. Jacobs, and P. C. Appelbaum. 2000. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:2740-2746.[Abstract/Free Full Text]
    26. 26
  26. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 6th ed. M7-A6, M100-S13. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    27. 27
  27. Oh, W. S., J. Y. Suh, J.-H. Song, K. S. Ko, S.-I. Jung, K. R. Peck, N. Y. Lee, Y. Yang, A. Chongthaleong, C.-H. Chiu, A. Kamarulzaman, N. Parasakthi, M. K. Lalitha, J. Perera, T. T. Yee, G. Kumarasinghe, C. C. Carlos, and the ANSORP Study Group. 2004. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae from Asian countries: ANSORP study. Microb. Drug Resist. 10:37-42.[CrossRef][Medline]
    28. 28
  28. Pan, X.-S., and L. M. Fisher. 1996. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178:4060-4069.[Abstract/Free Full Text]
    29. 29
  29. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.[Abstract]
    30. 30
  30. Pankuch, G. A., B. Bozdogan, K. Nagai, A. Tambic-Andrasevic, S. Schoenwald, T. Tambic, S. Kalenic, S. Plesko, N. K. Tepes, Z. Kotarski, M. Payerl-Pal, and P. C. Appelbaum. 2002. Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia. Antimicrob. Agents Chemother. 46:2671-2675.[Abstract/Free Full Text]
    31. 31
  31. Pestova, E., R. Beyer, N. P. Cianciotto, G. A. Noskin, and L. R. Peterson. 1999. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob. Agents Chemother. 43:2000-2004.[Abstract/Free Full Text]
    32. 32
  32. Pletz, M. W. R., L. McGee, J. Jorgensen, B. Beall, R. R. Facklam, C. G. Whitney, K. P. Klugman, and the Active Bacterial Core Surveillance Team. 2004. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob. Agents Chemother. 48:3491-3497.[Abstract/Free Full Text]
    33. 33
  33. Sahm, D. F., D. E. Peterson, I. A. Critchley, and C. Thorsberry. 2000. Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States. Antimicrob. Agents Chemother. 44:2521-2524.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, May 2005, p. 2126-2129, Vol. 49, No. 5
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.5.2126-2129.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Izdebski, R., Sadowy, E., Fiett, J., Grzesiowski, P., Gniadkowski, M., Hryniewicz, W. (2007). Clonal Diversity and Resistance Mechanisms in Tetracycline-Nonsusceptible Streptococcus pneumoniae Isolates in Poland. Antimicrob. Agents Chemother. 51: 1155-1163 [Abstract] [Full Text]  
  • Sadowy, E., Izdebski, R., Skoczynska, A., Grzesiowski, P., Gniadkowski, M., Hryniewicz, W. (2007). Phenotypic and Molecular Analysis of Penicillin-Nonsusceptible Streptococcus pneumoniae Isolates in Poland. Antimicrob. Agents Chemother. 51: 40-47 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sadowy, E.
Right arrow Articles by Hryniewicz, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sadowy, E.
Right arrow Articles by Hryniewicz, W.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»